VMA21 antibody
Quick Overview for VMA21 antibody (ABIN7254226)
Target
See all VMA21 AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Characteristics
- Polyclonal Antibody
-
Purification
- Antigen affinity purification
-
Immunogen
- Synthetic peptide of human VMA21
-
Isotype
- IgG
-
-
-
-
Application Notes
- IHC 1:150-1:500, IF 1: 50-1:200, ELISA 1:5000-1:240000
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 2.6 mg/mL
-
Buffer
- PBS with 0.05 % Sodium azide and 40 % Glycerol, pH 7.4
-
Preservative
- Sodium azide
-
Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Storage
- -20 °C
-
Storage Comment
- Store at -20°C. Avoid freeze / thaw cycles.
-
-
- VMA21 (Vacuolar H+-ATPase Homolog (VMA21))
-
Alternative Name
- VMA21
-
Background
- This gene encodes a chaperone for assembly of lysosomal vacuolar ATPase. Required for the assembly of the V0 complex of the vacuolar ATPase (V-ATPase) in the endoplasmic reticulum. Associates with the V0 complex of the vacuolar ATPase (V-ATPase). MEAX is a childhood-onset disease characterized by progressive vacuolation and atrophy of skeletal muscle. It is inherited in recessive fashion, affecting boys and sparing carrier females. Onset is in childhood, and patients exhibit weakness of the proximal muscles of the lower extremities, progressing slowly to involve other skeletal muscle groups over time.
-
UniProt
- Q3ZAQ7
Target
-